Skip to main content
SpringerLink
Log in

Interferon β-1a dominates no treatment for early MS

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

Interferon β-1a dominates no treatment for early MS. Pharmacoecon. Outcomes News 667, 10 (2012). https://doi.org/10.2165/00151234-201206670-00014

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-201206670-00014

Keywords

Search

Navigation